EUVIMEDEUVIMED entdecken
Video/AudioOpen Access · CC BY-NC 4.0

Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England’s prescription data during the COVID-19 pandemic (January 2019 to October 2020)

Ravina Barrett iD, James Hodgkinson

Therapeutic Advances in Cardiovascular Disease · 2022-01 · 16

DOI: 10.1177/17539447221137170 ↗

Kurz gefasst

Video/Audio in der Zeitschrift Therapeutic Advances in Cardiovascular Disease, online erschienen am 24.11.2022. Verfasst von Ravina Barrett und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Applied Sciences, University of Brighton, Cockcroft Building, Lewes Road, Moulsecoomb, Brighton BN2 4GJ, UK. Hauptthemen laut MEDLINE: COVID-19, Cardiovascular Agents, Cardiovascular Diseases, Heart Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Management of high blood pressure (BP) typically requires adherence to medication regimes. However, it is known that the COVID-19 pandemic both interrupted access to some routine prescriptions and changed some patient health behaviours.

Aim

This study, therefore, retrospectively investigated prescription reimbursement of cardiovascular (CVD) medicines as a proxy measure for patient adherence and access to medicines during the pandemic.

Methods

A cohort study of all primary care patients in England prescribed CVD medicines. The exposure was to the global pandemic. Prescriptions were compared before and after the pandemic’s onset. Statistical variation was the outcome of interest.

Results

Descriptive statistics show changes to monthly prescriptions, with wide confidence intervals indicating varying underlying practice. Analysis of variance reveals statistically significant differences for bendroflumethiazide, potassium-sparing diuretics, nicorandil, ezetimibe, ivabradine, ranolazine, colesevelam and midodrine. After the pandemic began (March–October 2020), negative parameters are observed for ACE inhibitors, beta-blockers, calcium channel blockers, statins, antiplatelet, antithrombotics, ARBs, loop diuretics, doxazosin, bendroflumethiazide, nitrates and indapamide, indicating decelerating monthly prescription items (statistically significant declines of calcium channel blockers, antithrombotic, adrenoreceptor blockers and diuretics) of CVD medicines within the general population. Many data points are not statistically significant, but fluctuations remain clinically important for the large population of patients taking these medications.

Conclusion

A concerning decline in uptake of CVD therapies for chronic heart disease was observed. Accessible screening and treatment alongside financial relief on prescription levies are needed. A video abstract is (4 min 51 s) available: https://bit.ly/39gvEHi

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Cardiovascular AgentsCardiovascular DiseasesHeart DiseasesHumansPandemicsAngiotensin-Converting Enzyme InhibitorsBendroflumethiazideRetrospective StudiesCohort StudiesAngiotensin Receptor AntagonistsDiureticsDrug Prescriptions

Stichwörter der Autor:innen

COVID-19SARS-CoV-2analysis of varianceangiotensin IIangiotensin-converting enzyme inhibitorsbendroflumethiazidecalcium channel blockerscardiovascular diseasescolesevelam hydrochloridecommunicable disease controlconfidence intervalsdelivery of health carediureticsdoxazosinezetimibe

Substanzen

Angiotensin-Converting Enzyme InhibitorsBendroflumethiazideAngiotensin Receptor AntagonistsCardiovascular AgentsDiuretics

Autor:innen und Institutionen

  • School of Applied Sciences, University of Brighton, Cockcroft Building, Lewes Road, Moulsecoomb, Brighton BN2 4GJ, UK.
  • Murray Learning Centre, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.

ORCID-Profile: Ravina Barrett

Zitieren

APA

Barrett, R., & Hodgkinson, J. (2022). Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England’s prescription data during the COVID-19 pandemic (January 2019 to October 2020). Therapeutic Advances in Cardiovascular Disease, 16. https://doi.org/10.1177/17539447221137170

Vancouver

Barrett R, Hodgkinson J. Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England’s prescription data during the COVID-19 pandemic (January 2019 to October 2020). Therapeutic Advances in Cardiovascular Disease. 2022;16. doi:10.1177/17539447221137170

BibTeX
@article{Barrett2022,
  author = {Barrett, Ravina and Hodgkinson, James},
  title = {Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England’s prescription data during the COVID-19 pandemic (January 2019 to October 2020)},
  journal = {Therapeutic Advances in Cardiovascular Disease},
  year = {2022},
  volume = {16},
  doi = {10.1177/17539447221137170}
}
Kostenlos starten →